The effect of barbiturates in patients with liver disease.
作者信息
SESSIONS J T, MINKEL H P, BULLARD J C, INGELFINGER F J
出版信息
J Clin Invest. 1954 Aug;33(8):1116-27. doi: 10.1172/JCI102985.
Abstract
摘要
相似文献
1
The effect of barbiturates in patients with liver disease.巴比妥类药物对肝病患者的影响。
J Clin Invest. 1954 Aug;33(8):1116-27. doi: 10.1172/JCI102985.
2
The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.成年囊性纤维化患者肝病的良性病程及熊去氧胆酸的作用
Liver Int. 2007 Dec;27(10):1402-8. doi: 10.1111/j.1478-3231.2007.01570.x.
3
Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases.肝病患者血清高尔基体蛋白-73表达升高的定量分析
Ann Clin Biochem. 2009 Jan;46(Pt 1):38-43. doi: 10.1258/acb.2008.008088. Epub 2008 Nov 13.
4
Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation.终末期肝病及肝移植后的自主神经和周围神经病变
Muscle Nerve. 2003 Nov;28(5):595-600. doi: 10.1002/mus.10477.
5
Impact of diabetes on the severity of liver disease.糖尿病对肝脏疾病严重程度的影响。
Am J Med. 2007 Oct;120(10):829-34. doi: 10.1016/j.amjmed.2007.03.025.
6
Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease.内毒素受体CD14和TLR4基因变异在慢性肝病中的相关性
Scand J Gastroenterol. 2008;43(5):584-92. doi: 10.1080/00365520701806065.
7
[Immunization guidelines in patients with chronic liver diseases].[慢性肝病患者的免疫接种指南]
Rev Med Suisse. 2007 Sep 5;3(123):1948, 1950-1.
8
Nutritional support in patients with chronic liver disease.慢性肝病患者的营养支持
Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9. doi: 10.1038/ncpgasthep0443.
9
Detection of Helicobacter species in chronic liver disease and chronic inflammatory bowel disease.慢性肝病和慢性炎症性肠病中幽门螺杆菌属的检测
Ann Med. 2007;39(7):554-60. doi: 10.1080/07853890701545714.
10
Preoperative evaluation of patients with liver disease.肝病患者的术前评估。
Nat Clin Pract Gastroenterol Hepatol. 2007 May;4(5):266-76. doi: 10.1038/ncpgasthep0794.
引用本文的文献
1
To-day's Drugs.当今的药物
Br Med J. 1963 Jan 5;1(5322):39-40.
2
HEPATIC coma; presentation and discussion of case.肝昏迷；病例介绍与讨论
Am J Dig Dis. 1958 Feb;3(2):159-77.
3
[The break-down of pentobarbital in hepatic diseases].
Klin Wochenschr. 1970 May 1;48(9):565-7. doi: 10.1007/BF01488573.
4
[Pharmacokinetics of meprobamate in chronic liver diseases and drug addiction].[眠尔通在慢性肝病和药物成瘾中的药代动力学]
Klin Wochenschr. 1969 Jan 15;47(2):78-80. doi: 10.1007/BF01745770.
5
[Changes in the velocity of drug catabolism and their importance in drug therapy].[药物分解代谢速度的变化及其在药物治疗中的重要性]
Klin Wochenschr. 1971 Apr 1;49(7):384-96. doi: 10.1007/BF01484994.
6
Metabolism of amylobarbitone in patients with chronic liver disease.慢性肝病患者中异戊巴比妥的代谢
Br J Pharmacol. 1972 Mar;44(3):549-60. doi: 10.1111/j.1476-5381.1972.tb07292.x.
7
Safe prescribing in liver disease.肝病的安全处方
Br Med J. 1973 Apr 28;2(5860):193-4.
8
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.慢性肝病中安替比林、对乙酰氨基酚和利多卡因的消除情况。
Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384.
9
Protein binding and kinetics of drugs in liver diseases.肝脏疾病中药物的蛋白结合与动力学
Clin Pharmacokinet. 1977 Jan-Feb;2(1):32-44. doi: 10.2165/00003088-197702010-00003.
本文引用的文献
1
An effect of barbiturates on serum cholinesterase.巴比妥类药物对血清胆碱酯酶的影响。
J Physiol. 1943 Dec 31;102(3):259-68. doi: 10.1113/jphysiol.1943.sp004031.
2
THE ESTIMATION OF SERUM SODIUM FROM BICARBONATE PLUS CHLORIDE.通过碳酸氢根离子和氯离子估算血清钠浓度
J Clin Invest. 1947 Sep;26(5):983-90. doi: 10.1172/JCI101893.
3
THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN.人体肝血流量的估计
J Clin Invest. 1945 Nov;24(6):890-7. doi: 10.1172/JCI101676.
4
Further studies on factors influencing liver injury and liver repair.关于影响肝损伤和肝修复因素的进一步研究。
Ann Surg. 1950 Sep;132(3):362-73. doi: 10.1097/00000658-195009000-00004.
5
Measurement of serum cholinesterase activity in the study of diseases of the liver and biliary system.肝脏和胆道系统疾病研究中血清胆碱酯酶活性的测定。
Gastroenterology. 1950 Jun;15(2):304-15.
6
The fate of pentobarbital in man and dog and a method for its estimation in biological material.戊巴比妥在人和狗体内的代谢情况及其在生物材料中的测定方法。
J Pharmacol Exp Ther. 1953 Sep;109(1):26-34.
Zotero 插件